Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 6:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 74 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Absorption, Metabolism and Excretion in Healthy Volunteers Clear all

Conditions: Healthy Volunteers, Healthy
Interventions: GC4419; Drug
Lead sponsor: Galera Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: [14C]-brensocatib; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Safety and Pharmacokinetics in Healthy Volunteer Subjects
Interventions: CC-223; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Participants
Interventions: BMS-986369; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]AR882; Drug
Lead sponsor: Arthrosi Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteers
Interventions: [14C]-AG-120; Drug
Lead sponsor: Agios Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteer
Interventions: GDC-0032; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: tucatinib; Drug
Lead sponsor: Cascadian Therapeutics Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteer
Interventions: Period 1 treatment, Period 2 treatment; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteer
Interventions: NX-5948; Drug
Lead sponsor: Nurix Therapeutics, Inc.; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteer
Interventions: [14C]-GDC-0980; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]-BMS-986368; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: MYK-224; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Subjects
Interventions: Tavapadon tablet, Tavapadon [14C] suspension; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: [14C]PF00299804; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Healthy Participant
Interventions: PF-07220060; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: BI 207127 NA; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: [14C]-Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteer, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, Inborn
Interventions: EDG-5506 Tablet, Radiolabeled EDG-5506 Suspension, Radiolabeled EDG-5506 Intravenous; Drug
Lead sponsor: Edgewise Therapeutics, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteer
Interventions: GDC-0941; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Volunteers
Interventions: [14C]-praliciguat; Drug
Lead sponsor: Cyclerion Therapeutics; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy Subject
Interventions: HMS5552; Drug
Lead sponsor: Hua Medicine Limited; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Volunteer
Interventions: GDC-0973; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Samidorphan IV, [14c]-Samidorphan sublingual, [14c]-Samidorphan oral; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Austin, Texas

Search by objective public record fields.

A Study to Investigate the Absorption, Metabolism, Excretion, and Mass Balance of GC4419 in Healthy Adult Subjects

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects

A Study to Evaluate the Metabolism and Excretion of BMS-986369 in Healthy Male Participants

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-AG-120

A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

A Phase I Bioavailability and Pharmacokinetic Study of [14C]-Ipatasertib Single Oral and Intravenous Doses in Healthy Male Subjects

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0980 Following Single Oral Dose Administration in Healthy Postmenopausal Female Subjects

A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

An Open-label Trial to Evaluate Mass Balance of Tavapadon at Steady State in Healthy Subjects

A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers

A Study to Compare Two Tablet Formulations of Study Medicine Atirmociclib in Healthy Participants

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male Subjects

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-GDC-0941 Following Single Oral Dose Administration in Healthy Male Subjects

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers

Human Mass Balance Study of HMS5552 in Healthy Subjects

A Pharmacokinetics Study of Radioactive-Labeled GDC-0973 in Healthy Male Volunteers

A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers